论文部分内容阅读
目的观察伊立替康联合卡培他滨治疗晚期大肠癌的疗效和不良反应。方法46例均为失去手术或再次手术治疗机会的有可测量病灶的晚期大肠癌患者。伊立替康60 mg/m2,第1、8天静脉滴注;卡培他滨2 500 mg/m2,分早晚2次口服,第1~14天,3周为一周期。结果38例患者完全缓解3例,部分缓解14例,疾病稳定14例,疾病稳定>6个月9例,疾病进展7例,近期有效率(完全缓解+部分缓解)为44.7%,临床获益率为68.4%。不良反应主要为恶心与呕吐、迟发性腹泻、粒细胞减少,多为Ⅰ~Ⅱ度。结论伊立替康联合卡培他滨的方案疗效高,不良反应患者能耐受,临床可以广泛推广应用。
Objective To observe the efficacy and adverse reactions of irinotecan combined with capecitabine in the treatment of advanced colorectal cancer. Methods All 46 patients with advanced colorectal cancer with measurable disease who lost their chance of surgery or reoperation. Irinotecan 60 mg / m2, intravenous infusion on the first and eighth days; capecitabine 2 500 mg / m2, points twice daily morning and evening, the first to 14 days, three weeks for a cycle. Results 38 patients were completely relieved in 3 cases, partial remission in 14 cases, stable disease in 14 cases, stable disease> 6 months in 9 cases, disease progression in 7 cases, the recent effective rate (complete remission + partial remission) was 44.7% The rate was 68.4%. Adverse reactions mainly nausea and vomiting, delayed diarrhea, neutropenia, mostly Ⅰ ~ Ⅱ degrees. Conclusion The irinotecan combined with capecitabine has high curative effect and patients with adverse reactions can tolerate. The clinical application can be widely promoted.